Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Inclusion Criteria: * Adults aged 19 to 80 years at the time of informed consent * Adults with type 2 diabetes not using insulin * Patients treated with GLP-1 agonist, oral hypoglycemic agents, and/or lifestyle modifications * Patients who have maintained stable diabetes treatment for at least 3 months without changes * HbA1c between 7.5% and 10.0% * Willing to wear personal continuous glucose monitoring device (CGM) * Willing to install and use CGM-linked app on personal smartphone with continuous access to WIFI or cellular data * Able to read and write Korean as judged by investigator * Willing to use medically acceptable contraception until end of study (sterile status, intrauterine device, or concurrent use of male/female barrier method with spermicide) * Fully informed about the clinical trial and voluntarily consenting to participate Exclusion Criteria: * Type 1 diabetes mellitus * Gestational diabetes mellitus * History of pancreatectomy * Continuous or intermittent insulin therapy for 7 days or more within 3 months * Oral or IV steroid treatment within 1 month prior to informed consent * Serious infection, surgery (scheduled or history), or severe trauma within 3 months prior to informed consent * History of malignancy within 1 year prior to informed consent (except thyroid cancer) * On hemodialysis or peritoneal dialysis or eGFR \< 30 mL/min/1.73m2 * Unable to avoid the following concomitant medications, devices, or treatments during the study: CGM other than study device, X-ray/MRI/CT scans, radiofrequency thermal therapy, implantable devices such as pacemakers, immunosuppressants, steroids, IV vitamin preparations, cancer treatment, hemodialysis/peritoneal dialysis, insulin therapy * Uncontrolled thyroid disease or clinically significant severe endocrine disorders (Cushing's syndrome, pheochromocytoma, etc.) * Severe allergic reaction to skin adhesives (e.g., dyspnea, severe rash, edema) * Whole blood donation within 60 days, apheresis within 30 days, or blood transfusion within 90 days prior to device application * Judged by investigator as unable to handle continuous glucose monitoring device * Pregnant or lactating women * Planning pregnancy within 1 year * Otherwise judged by investigator as inappropriate for participation in this clinical trial